CYCN Stock Overview
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.
+ 2 more risks
Cyclerion Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.56|
|52 Week High||US$4.86|
|52 Week Low||US$0.50|
|1 Month Change||-43.50%|
|3 Month Change||-50.87%|
|1 Year Change||-80.78%|
|3 Year Change||-96.13%|
|5 Year Change||n/a|
|Change since IPO||-95.48%|
Recent News & Updates
|CYCN||US Biotechs||US Market|
Return vs Industry: CYCN underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CYCN underperformed the US Market which returned -10.4% over the past year.
|CYCN Average Weekly Movement||11.9%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CYCN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CYCN's weekly volatility (12%) has been stable over the past year.
About the Company
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS.
Cyclerion Therapeutics Fundamentals Summary
|CYCN fundamental statistics|
Is CYCN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYCN income statement (TTM)|
|Cost of Revenue||US$35.34m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.18|
|Net Profit Margin||-1,115.79%|
How did CYCN perform over the long term?See historical performance and comparison
Is Cyclerion Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: CYCN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CYCN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYCN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYCN is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (1.4x).
How is Cyclerion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYCN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYCN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYCN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYCN's revenue (76.4% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: CYCN's revenue (76.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYCN's Return on Equity is forecast to be high in 3 years time
How has Cyclerion Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYCN is currently unprofitable.
Growing Profit Margin: CYCN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CYCN has a negative Return on Equity (-138.32%), as it is currently unprofitable.
How is Cyclerion Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CYCN's short term assets ($42.8M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: CYCN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CYCN is debt free.
Reducing Debt: CYCN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYCN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CYCN has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.9% each year.
What is Cyclerion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYCN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYCN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CYCN has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Hecht (57 yo)
Dr. Peter M. Hecht, Ph D., served as the Chief Executive Officer of Ironwood Pharmaceuticals, Inc. since 1998 until April 1, 2019. Dr. Hecht is Chief Executive Officer and Director of Cyclerion Therapeutic...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD108.22K) is below average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: CYCN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: CYCN's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.
Cyclerion Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Cyclerion Therapeutics, Inc.
- Ticker: CYCN
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$24.548m
- Shares outstanding: 43.45m
- Website: https://www.cyclerion.com
Number of Employees
- Cyclerion Therapeutics, Inc.
- 245 First Street
- 18th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.